Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Neoplasms of the CNS

  Free Subscription


29.04.2019

3 Br J Neurosurg
1 Eur J Cancer
1 Int J Cancer
2 Int J Radiat Oncol Biol Phys
3 J Neurooncol
3 J Neurosurg
1 Neurology
2 Neuroradiology
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Br J Neurosurg

  1. BURFORD C, Laxton R, Sidhu Z, Aizpurua M, et al
    ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
    Br J Neurosurg. 2019 Apr 24:1-5. doi: 10.1080/02688697.2019.1600657.
    PubMed     Text format     Abstract available

  2. KOZIARSKI A, Podgorski A, Zielinski GM
    Surgical treatment of pineal cysts in non-hydrocephalic and neurologically intact patients: selection of surgical candidates and clinical outcome.
    Br J Neurosurg. 2019;33:37-42.
    PubMed     Text format     Abstract available

  3. ALKAN A, Yazici G, Cengiz M, Karakas Y, et al
    The role of ABO blood groups in glial neoplasms.
    Br J Neurosurg. 2019;33:43-46.
    PubMed     Text format     Abstract available


    Eur J Cancer

  4. PFAFF E, El Damaty A, Balasubramanian GP, Blattner-Johnson M, et al
    Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.
    Eur J Cancer. 2019;114:27-35.
    PubMed     Text format     Abstract available


    Int J Cancer

  5. VINCHURE OS, Sharma V, Tabasum S, Ghosh S, et al
    Polycomb complex mediated epigenetic reprogramming alters TGF-beta signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
    Int J Cancer. 2019 Apr 22. doi: 10.1002/ijc.32360.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  6. BALLO MT, Urman N, Lavy-Shahaf G, Bomzon Z, et al
    Correlation of Tumor Treating Fields dosimetry to survival outcomes in newly diagnosed glioblastoma: A large-scale numerical simulation-based analysis of data from the Phase 3 EF-14 randomized trial.
    Int J Radiat Oncol Biol Phys. 2019 Apr 23. pii: S0360-3016(19)30629.
    PubMed     Text format     Abstract available

  7. TOM MC, Varra V, Leyrer CM, Park DY, et al
    Risk Factors for Progression Among Low-Grade Gliomas Following Gross Total Resection and Initial Observation in the Molecular Era.
    Int J Radiat Oncol Biol Phys. 2019 Apr 22. pii: S0360-3016(19)30631.
    PubMed     Text format     Abstract available


    J Neurooncol

  8. SAK M, Zumbar CT, King PD, Li X, et al
    Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.
    J Neurooncol. 2019 Apr 22. pii: 10.1007/s11060-019-03164.
    PubMed     Text format     Abstract available

  9. HUNG YC, Lee CC, Guo WY, Shiau CY, et al
    Gamma knife radiosurgery for the treatment of cavernous sinus meningiomas: post-treatment long-term clinical outcomes, complications, and volume changes.
    J Neurooncol. 2019 Apr 24. pii: 10.1007/s11060-019-03090.
    PubMed     Text format     Abstract available

  10. WU A, Maxwell R, Xia Y, Cardarelli P, et al
    Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    J Neurooncol. 2019 Apr 25. pii: 10.1007/s11060-019-03172.
    PubMed     Text format     Abstract available


    J Neurosurg

  11. SUERO MOLINA E, Ewelt C, Warneke N, Schwake M, et al
    Dual labeling with 5-aminolevulinic acid and fluorescein in high-grade glioma surgery with a prototype filter system built into a neurosurgical microscope: technical note.
    J Neurosurg. 2019 Apr 26:1-7. doi: 10.3171/2018.12.JNS182422.
    PubMed     Text format     Abstract available

  12. SERIZAWA T, Yamamoto M, Higuchi Y, Sato Y, et al
    Local tumor progression treated with Gamma Knife radiosurgery: differences between patients with 2-4 versus 5-10 brain metastases based on an update of a multi-institutional prospective observational study (JLGK0901).
    J Neurosurg. 2019 Apr 26:1-10. doi: 10.3171/2019.1.JNS183085.
    PubMed     Text format     Abstract available

  13. LI C, Wang S, Yan JL, Torheim T, et al
    Characterizing tumor invasiveness of glioblastoma using multiparametric magnetic resonance imaging.
    J Neurosurg. 2019 Apr 26:1-8. doi: 10.3171/2018.12.JNS182926.
    PubMed     Text format     Abstract available


    Neurology

  14. ANDERSEN BM, Miranda C, Hatzoglou V, DeAngelis LM, et al
    Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience.
    Neurology. 2019 Apr 24. pii: WNL.0000000000007529.
    PubMed     Text format     Abstract available


    Neuroradiology

  15. HASSE A, Dapash M, Jeong Y, Ansari SA, et al
    Correlation of post-contrast T1-weighted MRI surface regularity, tumor bulk, and necrotic volume with Ki67 and p53 in glioblastomas.
    Neuroradiology. 2019 Apr 24. pii: 10.1007/s00234-019-02204.
    PubMed     Text format     Abstract available

  16. MARSAULT P, Ducassou S, Menut F, Bessou P, et al
    Correction to: Diagnostic performance of an unenhanced MRI exam for tumor follow-up of the optic pathway gliomas in children.
    Neuroradiology. 2019 Apr 22. pii: 10.1007/s00234-019-02214.
    PubMed     Text format     Abstract available


    PLoS One

  17. SAINI J, Gupta RK, Kumar M, Singh A, et al
    Comparative evaluation of cerebral gliomas using rCBV measurements during sequential acquisition of T1-perfusion and T2*-perfusion MRI.
    PLoS One. 2019;14:e0215400.
    PubMed     Text format     Abstract available

  18. JUNG E, de Los Reyes V AA, Pumares KJA, Kim Y, et al
    Strategies in regulating glioblastoma signaling pathways and anti-invasion therapy.
    PLoS One. 2019;14:e0215547.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: